Real-world outcomes of melanoma surveillance using the MoleMap NZ telemedicine platform

Total body photography for the diagnosis of cutaneous melanoma in adults: a systematic review and meta‐analysis*

“…5,7,8,[11][12][13][19][20][21][22] Included studies were from the USA (n = 6), 5,7,8,11,12,21 Australia (n = 1), 22 New Zealand (n = 1), 20 Greece (n =1) 13 and Spain (n = 1). 19 Seven studies were retrospective 5,8,11,12,[19][20][21] and three were prospective, 7,13,22 with data collection ranging from 1998 to 2018. Median follow-up periods ranged from 12 to 96 months.…”

“…The protocols used for TBP in each of the studies examined varied widely, with five studies complementing TBP with sequential dermoscopic images (Table 1). 12,13,19,20,22 One study used computer-assisted automation to aid serial acquisition of TBP images. 12 No studies reported using artificial intelligence (AI) algorithms to classify images as benign vs. malignant.…”

“…5,7,13,19,21 Median BT ranged from 0Á33 mm to 0Á50 mm for three studies reporting median BT. 8,20,22 Only three studies reported body location for melanoma; 180 (48Á1%) were located on extremities, 160 (43Á3%) on the trunk and 32 (8Á6%) on the head or neck. 5,20,22 Only two studies reported melanoma subtype.…”

Melanoma surveillance for high-risk patients via telemedicine: Examination of real-world data from an integrated store-and-forward total body photography and dermoscopy service

“…1 We recently reported the performance of a proprietary, New Zealand-based telemedicine platform (MoleMap NZ) that integrates total body photography and dermoscopy to help address the country's high incidence of melanoma. 2 It allows dermatologists specializing in pigmented lesions to provide store-and-forward telemedicine consultations to patients and referring doctors. Here, we conducted a preliminary review of a United States-based melanoma surveillance service named MoleSafe USA, which uses this platform (Institutional Review Board protocol #11-01905).…”

“…Lesions meeting a set of predefined, mainly morphologic criteria are imaged clinically and dermoscopically. 2 The images are stored and forwarded to a pigmented lesion expert who reviews each lesion and recommends biopsy/excision for lesions suspicious for melanoma or other skin cancer, or follow-up in 3 months for dermoscopic monitoring for lesions of only slight suspicion. 3 These recommendations are provided to the patient and referring clinician via a written report.…”